Trial Profile
Phase II Clinical Trial of Eribulin in Advanced or Recurrent Cervical Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Nov 2021
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Cervical cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Nov 2021 Status changed from active, no longer recruiting to completed.
- 17 Jun 2019 Planned End Date changed from 9 Aug 2020 to 9 Aug 2021.
- 17 Jun 2019 Planned primary completion date changed from 9 Aug 2019 to 9 Aug 2020.